A Phase 4 interventional study of Triple therapy in Helicobacter Pylori Infections, Atrophic Gastritis and Gastric Cancer, sponsored by International Agency for Research on Cancer. Recruiting at 1 site in Latvia. Open to participants aged 40 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-02.
Sponsored by International Agency for Research on Cancer · Phase 4, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Currently no ideal preventive modalities are available for reducing gastric-cancer caused mortality in organized population-based application. The primary objective of the study is to determine if H.pylori screening followed by eradication of positive subjects and endoscopic follow-up of those with serological evidence of atrophic gastritis reduces mortality from gastric cancer in middle-aged people in high-risk areas. The GISTAR study is a multicenter randomized study of H.pylori eradication and pepsinogen testing for prevention of gastric cancer mortality. Altogether 30.000 individuals aged 40-64 years will be enrolled, providing 90% study power to detect at least 35% reduction in gastric cancer mortality at 15 years of follow-up. Participants will be randomly allocated to one of two groups. In the active investigation/management group those positive for H.pylori will be offered eradication therapy and individuals with decreased pepsinogen I/II ratio will be invited for endoscopy. The control group will receive standard health care. The primary endpoint for this trial will be the mortality difference from gastric cancer between the two groups at 15 years or when enough cases accumulate to demonstrate a statistical difference. The study is expected to provide valuable information on the utility for reduction in gastric cancer mortality of: 1) H.pylori eradication in adults on a population-basis, including subjects who may already have pre-malignant lesions; and 2) pepsinogen testing in screening settings. A pilot study of 3,455 individuals prior to the main trial was conducted from October 2013 to December 2016.
Gastric cancer is an important global public health issue in Eastern European regions, where the burden of the disease is substantial. There is sufficient epidemiological and experimental evidence that supports a causal link between H. pylori and gastric cancer. However, there is still limited evidence from clinical trials to prove whether H. pylori eradication with antimicrobial therapy is the approach of choice in entire infected populations or only in selected groups to reduce the risk of gastric cancer and whether eradication at advanced stages of atrophy is effective among these patients. The current European and global guidelines are proposing screening with pepsinogen tests as the best available tool to identify the individuals at increased risk for cancer development, yet there is insufficient evidence available on how effective these tests are in organized cancer screening settings.
We therefore propose to conduct a multi-center randomized trial in Latvia, Belarus and Russia, areas with high burden of the disease, with the main objective of evaluating if H. pylori screening followed by eradication in participants with positive result and endoscopy of those with serological evidence of atrophic gastritis can reduce gastric cancer mortality. The proposed trial will also investigate retrospectively if groups with chronic atrophic gastritis can select subjects who require treatment to achieve comparable gastric cancer reduction. Ultimately, this study will have the potential to find effective prevention strategies through identifying appropriate target groups that could get most benefits from the treatment.
The aim of this study is to search for new intervention strategies to decrease mortality from gastric cancer in high-risk areas.
The primary objective of the study is to determine if H. pylori screening followed by eradication of positive subjects and endoscopic follow-up of those with serological evidence of atrophic gastritis reduces mortality from gastric cancer in a high risk population among 40-64 years old subjects.
The secondary objectives are:
Methods: Approximately 30,000 men and women will be recruited into a randomized study. Eligible subjects between 40-64 years of age at entry who are residents in high gastric cancer incidence areas will be invited to participate in the trial by visiting one of the study clinics set up specifically for this trial.
For eligible participants who agree to participate and sign informed consent, a risk factor questionnaire will be administered and a complete medical evaluation will be performed at baseline.
Participants will be randomly assigned to either Group 1 (50%) or Group 2 (50%). Among those assigned to Group 1, H. pylori screening by detecting immunoglobulin G (IgG) group antibodies in plasma/serum and pepsinogen test will be performed. According to the results of the tests, participants will be assigned to H. pylori eradication treatment or upper endoscopy. Participants with serological evidence of atrophic gastritis (low pepsinogen I/II ratio) will undergo upper endoscopy with appropriate biopsy sampling as well as further follow-up with endoscopy according to MAPS (Management of precancerous conditions and lesions in the stomach) guidelines. H. pylori positive individuals will be offered standard eradication treatment as appropriate. From subjects in this group, breath samples will also be collected for volatile markers study by research nurses or junior physicians.
Participants assigned to Group 2 (50%) will constitute the control group, after having had a medical evaluation at the time of recruitment. During the follow-up period this group will be offered to consult a specialist when required due to clinical symptoms.
Both Group 1 and Group 2 will be offered fecal occult blood test (FOBT) as a benefit of study participation. Any participants who show a positive FOBT result will be referred to colonoscopy.
All the trial participants including Group 2 will be followed up at least for 15 years to collect systematic information on medical conditions, in particular gastric cancer and cause of death. A follow-up telephone call /alternative communication will be made every 5 years for outcome assessment.
The general study is preceded by a pilot-study that was conducted from October 2013 to December 2016 to test the assumptions as well as the tools and functionality of the study infrastructure. According to the results of the pilot study, required infrastructure and tools planned in the general study will be adapted accordingly.
Endpoints: The primary endpoint for our trial will be the mortality difference from gastric cancer between Group 1 and Group 2 at 15 years or when enough cases accumulate to demonstrate a statistical difference between the groups.
In addition to the mortality difference from gastric cancer between the two groups, other endpoints required to achieve the secondary objectives are listed below:
A pilot study with 3,455 participants was started in October 2013 and completed in December 2016 in Latvia.
77 studies on the registry are indexed under Gastritis, Atrophic; 38 are open to participants now.
This study's planned enrollment of 30,000 is above the median of 91 across 21 interventional studies indexed under Gastritis, Atrophic.
Browse Gastritis, Atrophic studies →International Agency for Research on Cancer is the lead sponsor of 30 studies on the registry; 9 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Among those assigned to Group 1, participants who are Helicobacter pylori positive will receive Triple therapy and/or upper endoscopy. Participants with serological evidence of atrophic gastritis will undergo upper endoscopy and further endoscopic follow-up. H. pylori positive individuals will be offered Helicobacter pylori eradication as appropriate, independently of the pepsinogen results. From subjects in this group, breath samples will also be collected for volatile markers study. In addition, fecal occult blood test (FOBT) will be offered to this group as a benefit to participate in the study.
Drug: Triple therapy
Those who assigned to Group 2 will receive no intervention and will be offered FOBT as a benefit of study participation. Any participants who show positive FOBT will be referred to colonoscopy. This will be the benefit to this group together with initial medical evaluation at the time of inclusion. During the follow-up period this group will be offered to consult a specialist when required due to clinical symptoms.
Participants who are positive with Helicobacter pylori in Group1 will receive triple therapy. * Esomeprazole 40 mg bid for 10 days * Clarithromycin 500 mg bid for 10 days * Amoxicillin 1000 mg bid for 10 days
Gastric cancer mortality
The primary objective of the study is to determine if H. pylori screening followed by eradication of positive subjects and endoscopic follow-up of those with serological evidence of atrophic gastritis reduces mortality from gastric cancer in a high risk population among 40-64 years old subjects.
Time frame: 15 years
Gastric cancer incidence
The difference in gastric cancer incidence between Group 1 and Group 2 will be investigated
Time frame: 15 years
All-cause mortality
The all-cause mortality difference between Group 1 and Group 2 will also be investigated.
Time frame: 15 years
Incidence of- and mortality from other medical conditions
The impact of H. pylori eradication on selected medical conditions potentially associated with the infection (e.g. obesity, inflammatory bowel disease, dementia, circulatory diseases and esophageal diseases) will be explored.
Time frame: 15 years
Started Mar 2013 (actual). Primary completion is estimated for Dec 2033, 249 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
International Agency for Research on Cancer